Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162206 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4ALDH1A1CES2 | |
| SCHEMBL374209 | 0.85 | GABRA1 (0.56) | GABRA1GABRB2CYP3A4ACHETRPA1 | |
| SCHEMBL15589311 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4ACHEMEN1 | |
| SCHEMBL1133364 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4ACHETRPA1 | |
| SCHEMBL28201284 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4ACHETRPA1 | |
| SCHEMBL30520271 | 0.78 | CYP3A4 (0.63) | GABRA1GABRB2CYP3A4ACHETRPA1 | |
| SCHEMBL20145 | 0.78 | CYP3A4 (0.63) | GABRA1GABRB2CYP3A4ACHETRPA1 | |
| SCHEMBL9630070 | 0.78 | CYP3A4 (0.52) | GABRA1GABRB2CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL30625397 | 0.78 | CYP3A4 (0.52) | GABRA1GABRB2CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL10614854 | 0.77 | GABRA1 (0.75) | GABRA1GABRB2CYP3A4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| CN-101378757-B | Thiadiazole derivatives for the treatment of neuro degenerative diseases | REMYND NV | 2012-08-01 | — | — | CN | disclosed |
| CN-101378757-A | Thiadiazole derivatives for the treatment of neuro degenerative diseases | REMYND NV (BE) | 2009-03-04 | — | — | CN | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| EP-0217787-A4 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-21 | — | — | EP | disclosed |
| EP-0217787-A1 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1987-04-15 | — | — | EP | disclosed |
| WO-1986004935-A1 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1986-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | GABRA1 1975/4885GABRB2 2934/4885CYP3A4 916/4885 |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | GABRA1 2321/4885GABRB2 3093/4885CYP3A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.